Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion

Haematologica

Volumn 84, Issue 1, 1999, Pages 80-84

  España, Francisco ^a   Vilia, Piedad ^a   Mira, Yolanda ^a   Grancha, Salvador ^a   Royo, Montserrat ^a   Estellés, Amparo ^a   Vayá, Amparo ^a   Aznar, Justo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Activated protein C resistance; Antiphospholipid antibodies; Factor V Leiden; Protein S deficiency; Recurrent abortion; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTEIN S;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CASE REPORT; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PROTEIN S DEFICIENCY; RECURRENT ABORTION; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ABORTION, HABITUAL; ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BETA 2-GLYCOPROTEIN I; BRAIN ISCHEMIA; CEREBRAL INFARCTION; FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HETEROZYGOTE; HUMANS; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN S; THROMBOPHILIA; THROMBOPHLEBITIS;

EID: 0032833188     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49:193-280.
2. Exner T, McRea J. Studies on the relationship between 'antiphospholipid' antibodies and the lupus anticoagulant. Blood Coagul Fibrinol 1990; 1:17-21.
3. Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid polystyrene column. Biochem Biophys Res Comm 1988; 155:1001-7.
4. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulant comprise antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73:506-13.
5. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
6. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87:4120-4.
7. Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 1990; 17:785-9.
8. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipidbound human prothrombin. Thromb Haemostas 1991; 66:629-32.
9. Bokarewa MI, Blomback M, Egberg N, Rose S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coagul Fibrinol 1994; 5:37-41.
10. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86:617-23.
11. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR. Thrombosis, RFL and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 1986; 146:2153-6.
12. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84:2854-67.
13. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 12:477-80.
14. Reitsma PH, Bernardi F, Doig RG, et al. Protein C deficiency: a data base of mutations, 1995 update. Thromb Haemostas 1995; 73:876-9.
15. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-8.
16. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-9.
17. Brenner B, Vulfsons SL, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 1996; 94:166-7.
18. Crowther MA, Johnston M, Weitz J, Ginsberg JS. Free protein S deficiency may be found in patients with antiphospholipid antibodies who do not have systemic lupus erythematosus. Thromb Haemostas 1996; 76:689-91.
19. Harris EN. Special report. The second International Anti-Cardiolipin Standardization workshop - the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94:476-84.
20. Berard M, Chantome R, Marcelli A, Boffa MC. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23:1369-74.
21. Jorquera JI, Montoro JM, Fernández MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344:1162-3.
22. Aznar J, Villa P, España F, Estellés A, Grancha S, Falcó C. Activated protein C-resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997; 130:202-8.
23. Villa P, Aznar J, Jorquera JI, Casaña P. Laboratory diagnosis of APC-resistance in patients with lupus anticoagulant. Thromb Haemostas 1995; 74:1606-7.
24. Fernández JA, España F, Aznar J. Purificación de proteína S y obtención de anticuerpos anti-proteína S. Rev Diagnost Biol 1987; 36:19-22.
25. Sorice M, Arcieri P, Griggi T, et al. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb Haemostas 1996; 75:555-9.
26. España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays. Enzyme levels are proportional to total protein C level. Thromb Haemostas 1996; 75:56-61.
27. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg 506 Gln mutation. Blood Coagul Fibrinol 1995; 6:245-7.
28. Cumming AM, Keeney S, Salden A, Bhavnani M, Shwe KH, Hay CRM. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol 1997; 98:353-5.
29. Viard JP, Amoura Z, Bach JF. Association of anti-β2-glycoprotein-I antibodies in systemic lupus erythematous-a marker of thrombosis associated with lupus anticoagulant activity. C R Acad Sci (III) 1991; 313: 607-12.
30. Horbach DA, Oort EV, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Thromb Haemostas 1996; 76:916-24.
31. Morange PE, Alessi MC, Barthet MC, et al. Acquired protein S deficiency, likely due to anti-PS autoantibodies, following a thrombotic event in a patient with a systemic lupus erythematosus. Thromb Haemostas 1997; 78:1416-7.
32. Oosting JD, Derksen RHWM, Bobbink IWG, Kacheng TM, Bouma MN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 1993; 81:2618-25.
33. Calvin JB, Kurosawa S, Moore K, Esmon NL. Reconstitution of rabbit thrombomodulin into phospholipid vesicles. J Biol Chem 1987; 262:2199-205.
34. Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269:816-9.
35. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95:309-16.
36. Cariou R, Tobelem G, Belluci S, et al. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells - Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostas 1988; 60:54-8.
37. Comp CP, deBault LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 1983; 62 (Suppl. 1):299a.
38. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74:2426-32.
39. Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76:101-7.
40. Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91:1999-2004.
41. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemostas 1993; 70: 1067-71.